Detalhe da pesquisa
1.
Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma.
Blood
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38713888
2.
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
Eur J Haematol
; 110(5): 564-570, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36726221
3.
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.
Blood Cancer J
; 14(1): 87, 2024 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38811560
4.
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
JAMA Oncol
; 8(9): 1278-1286, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35862034
5.
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
Blood Cancer J
; 11(2): 19, 2021 02 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33563912